奥沙利铂联合恩度治疗中晚期非小细胞肺癌的疗效

目的 观察奥沙利铂联合恩度治疗中晚期非小细胞肺癌的疗效.方法 将收诊的68例中晚期非小细胞肺癌患者随机分成两组,对照组和观察组各34例.对照组采用多西他赛/奥沙利铂方案,观察组则采用奥沙利铂联合恩度治疗.比较两组近期疗效及不良反应发生率差异,化疗前及化疗后第2、5周对两组患者血清肿瘤标志物(CA125、CEA及CA242)水平进行检测,比较组间差异.结果 完成1个周期的化疗后观察组实体瘤部分缓解率、稳定率及总有效率明显高于对照组,而进展率则明显低于对照组,P<0.05.在治疗后的第2、5周,观察组患者血清肿瘤标志物CA125、CEA及CA242水平均显著低于对照组,P<0.05.两组患者间不良反应发生率无统计学差异,P>0.05.结论 奥沙利铂联合恩度治疗中晚期非小细胞肺癌能有效下调血清肿瘤标志物水平,提高疗效且不会加重不良反应的发生.

Efficacy of Oxaliplatin Combined with Endostar for Patients with Advanced Non-small Cell Lung Cancer

Objective To study the efficacy of oxaliplatin combined with endostar for patients with advanced non-small cell lung cancer.Methods Patients with advanced non-small cell lung cancer were selected in this research,these patients were randomly divided into the control group(34 patients,docetaxel/oxaliplatin treatment group)and the observation group(34 patients,oxaliplatin combined with endostar treatment group).Efficacy and toxicity incidence of the 2 groups were compared,the indicators of serum tumor markers such as CA125,CEA and CA242 were also been assessed and compared.Results After completing a cycle of chemotherapy,the rates of PR,SD and total efficiency of the observation group were higher than those of the control group,but the rates of PD was higher than those of the control group,and the indicators of serum tumor markers such as CA125,CEA and CA242 were significantly lower than those of the control group,all P<0.05.The incidence and types of adverse reactions between the 2 groups had no significant difference.Conclusion Oxaliplatin combined with endostar for patients with advanced non-small cell lung cancer can decrease the indicators of serum tumor markers,improve efficacy without increase adverse reactions.